Literature DB >> 27720840

Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases.

Jean-Frederic Colombel1, Neeraj Narula2, Laurent Peyrin-Biroulet3.   

Abstract

Strategies for management of inflammatory bowel diseases are shifting from simple control of symptoms toward full control of these diseases (clinical and endoscopic remission), with the final aim of blocking their progression and preventing bowel damage and disability. New goals have been proposed for treatment, such as treat to target and tight control based on therapeutic monitoring and early intervention. For patients who achieve clinical remission, there is often interest in discontinuation of therapy due to safety or economic concerns. We review the evidence supporting these emerging paradigms, the reasons that early effective treatment can alter progression of inflammatory bowel diseases, the importance of examining objective signs of inflammation, and the safety of reducing treatment dosage. We also discuss recent findings regarding personalization of care, including factors that predict patient outcomes and response to therapies, as well as preventative strategies.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Control; Dose; Efficacy; Intestine

Mesh:

Year:  2016        PMID: 27720840     DOI: 10.1053/j.gastro.2016.09.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  54 in total

1.  Innate γδT17 cells play a protective role in DSS-induced colitis via recruitment of Gr-1+CD11b+ myeloid suppressor cells.

Authors:  Xuan Sun; Yihua Cai; Chris Fleming; Zan Tong; Zhenglong Wang; Chuanlin Ding; Minye Qu; Huang-Ge Zhang; Jian Suo; Jun Yan
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

2.  Bacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn's Disease.

Authors:  Margaret Delday; Imke Mulder; Elizabeth T Logan; George Grant
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

3.  A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype.

Authors:  Sharif Yassin; Naomi Fliss Isakov; Yulia Ron; Nathaniel Aviv Cohen; Ayal Hirsch; Nitsan Maharshak
Journal:  Int J Colorectal Dis       Date:  2021-01-06       Impact factor: 2.571

4.  Inflammatory Bowel Disease Patient Experiences with Psychotherapy in the Community.

Authors:  Meredith R Craven; Sarah Quinton; Tiffany H Taft
Journal:  J Clin Psychol Med Settings       Date:  2019-06

5.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

6.  Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes.

Authors:  Fenfen Zhou; Therwa Hamza; Ashley S Fleur; Yongrong Zhang; Hua Yu; Kevin Chen; Jonathon E Heath; Ye Chen; Haihui Huang; Hanping Feng
Journal:  Inflamm Bowel Dis       Date:  2018-02-15       Impact factor: 5.325

7.  Endoscopic Balloon Dilation Size and Avoidance of Surgery in Stricturing Crohn's Disease.

Authors:  Bethany A Reutemann; Joshua A Turkeltaub; Mahmoud Al-Hawary; Akbar K Waljee; Peter D R Higgins; Ryan W Stidham
Journal:  Inflamm Bowel Dis       Date:  2017-10       Impact factor: 5.325

8.  Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease.

Authors:  Naazish S Bashir; Thomas D Walters; Anne M Griffiths; Shinya Ito; Wendy J Ungar
Journal:  Inflamm Bowel Dis       Date:  2020-07-17       Impact factor: 5.325

Review 9.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

10.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.